Re: Curious -- what was disclosed at conference that would cause a sell off?
All that was out on Saturday and available all day on the Conatus website.
If you are amused, go through the slide on the website.
Yes, it failed, but if you look at the results the drug does move most patients in the
right direction (lower HVPG) but just not quite enough except for in one small group.
I still say it works good enough and results predictable enough that someone (like Novartis) is
going to want the company for this drug.
Just bought more at .735. Sort of funny how many shares I have.